A study to investigate the effect of MEDI0382 on hepatic glycogen metabolism in overweight and obese subjects with Type 2 Diabetes Mellitus.

Study identifier:D5670C00022

ClinicalTrials.gov identifier:NCT03555994

EudraCT identifier:2017-005081-22

CTIS identifier:N/A

Study Complete

Official Title

An Exploratory Phase 2, Randomised, Double-blind, Placebo-controlled, and Open-label Active Comparator Study to Evaluate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects with Type 2 Diabetes Mellitus.

Medical condition

Type 2 Diabetes Mellitus

Phase

Phase 2

Healthy volunteers

No

Study drug

MEDI0382, Placebo, Liraglutide

Sex

All

Actual Enrollment

51

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 31 May 2018
Primary Completion Date: 14 Apr 2021
Study Completion Date: 14 Apr 2021

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

-

Inclusion and exclusion criteria